FlexWear is a cross-linked hydrocolloid skin barrier that provides aggressive adherence and is designed for more than one day weartime.
Inquire
Protects the skin over extended wearing time from irritating discharge. Flextend skin barrier is the barrier of choice for urostomies and ileostomies. Security and confidence assured with internal no
Protects the skin over extended wearing time from irritating discharge. Flextend skin barrier is the barrier of choice for urostomies and ileostomies with the added benefit of it being discreet in bo
Medicine Products:(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2(Date:9/3/2008)... Third Clinical Trial Reconfirms Strong Evidence ...w Have Lasting Effect on Joints Following Cessatio...OKEN, N.J., Sept. 3 /- According to t...s, the most common type of arthritis,is on the ri... Phytotherapy,Research, reveals Pycnogenol(R), bar...
(Date:9/3/2008)... MUNICH, Germany, Sept. 3 /PRNewswire-FirstCal...l trial showed that treatment with prasugrel,compa...k of new or,recurrent heart attacks (7.4 percent v...he events occurred around the time of an artery-op...ervention (PCI), or if they,occurred spontaneously...
(Date:9/2/2008)... PARIS, September 3 /-,...ne) Decreased the Risk,of Stroke by 34% in Patient...dy Adequately Treated by Antithrombotic Therapy, ...m the ATHENA study,were presented today at the cli... of Cardiology congress 2008, in Munich, Germany. ...
(Date:9/2/2008)... September is Prostate Cancer Awar.../- September is,Prostate Cancer Aware...d,Palm Beach announce a revolutionary new way to t...tment courses of radiation. Prostate cancer is,the...S., Morse CyberKnife CEO, James G. Schwade, M.D.,...
Breaking Medicine Technology:Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5The SCOOTER Store Donates Power Wheelchair to Paraplegic a Victim of Accidental Shooting 4480 1The SCOOTER Store Donates Power Wheelchair to Paraplegic a Victim of Accidental Shooting 4480 2Consumers Call On Interstate Stem Cell Group To Endorse Open Meetings 1469 1Consumers Call On Interstate Stem Cell Group To Endorse Open Meetings 1469 2Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 635 1Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 635 2Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 635 3Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 635 4Living with lions 945 1Living with lions 945 2...May 22, 2007 /PRNewswire/ -- Results from analyses...reatment of,ulcerative colitis (UC), were presen...oth of these studies were funded by Procter &,Ga... study,offer new information on improvement of q...ol(R) (mesalamine), which is from a class,of age...
...BUSINESS WIRE)--May 22, 2007 - Alequel(TM), an,ind...y be an,effective treatment for moderate-to-severe...uble-blind, placebo controlled Phase II,studies su...ood,clinical remissions and improved patients, qua...ers from Hebrew University-Hadassah,Medical Center...
Other Medicine Technology:Separate Sets of Research Show Treatment Improved Quality of Life,in as Early as Three Weeks; Patient Adherence to Medication is,Multifactorial 2Separate Sets of Research Show Treatment Improved Quality of Life,in as Early as Three Weeks; Patient Adherence to Medication is,Multifactorial 3Separate Sets of Research Show Treatment Improved Quality of Life,in as Early as Three Weeks; Patient Adherence to Medication is,Multifactorial 4Separate Sets of Research Show Treatment Improved Quality of Life,in as Early as Three Weeks; Patient Adherence to Medication is,Multifactorial 5Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 2Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 3